Biogen to Acquire Apellis Pharmaceuticals for $5.6B

Why It Matters

The acquisition diversifies Biogen’s revenue base and positions it in high‑growth rare‑disease segments, mitigating the decline of its flagship MS franchise.

Key Takeaways

• Biogen pays $5.6B cash for Apollis.
• Acquires Empaveli for rare kidney diseases.
• Gains Syfovre for advanced eye disorder.
• Combined 2023 revenue $689M, growth mid‑teens.
• Diversifies away from waning MS drug sales.

Pulse Analysis

Biogen’s $5.6 billion purchase of Apellis marks another high‑profile deal in a year where large biotech firms are reshaping portfolios through strategic acquisitions. After years of relying on multiple‑sclerosis therapies such as Tecfidera and Spinraza, the company has faced a gradual revenue slowdown as competition intensifies and patent cliffs loom. By turning to rare‑disease therapeutics, Biogen follows a broader industry pattern that values niche indications with premium pricing and limited competition. The cash‑only structure also signals confidence in Apellis’s near‑term cash flow generation.

Apellis brings two commercially launched assets: Empaveli, a complement inhibitor approved for atypical hemolytic uremic syndrome and C3 glomerulopathy, and Syfovre, an intravitreal injection for geographic atrophy, a leading cause of irreversible blindness. Together they produced roughly $689 million in 2023, and analysts forecast revenue expansion in the mid‑to‑high teens annually through 2028 as patient populations grow and reimbursement pathways mature. The kidney‑disease market alone is projected to exceed $10 billion globally, while the geographic atrophy segment offers a sizable unmet need that could drive premium pricing.

From a financial perspective, the deal adds a steady, high‑margin revenue stream that can offset the erosion of Biogen’s multiple‑sclerosis sales, which have been under pressure from generic entrants. The acquisition is expected to be accretive to earnings within two years, assuming the projected growth rates hold. For investors, the move reduces reliance on a single therapeutic area and aligns Biogen with the lucrative rare‑disease business model that has attracted premium valuations across the sector. In the longer term, the expanded pipeline may also enable further combination opportunities or innovative collaborations.

Deal Summary

Biogen announced on March 31, 2026 that it will acquire Apellis Pharmaceuticals for approximately $5.6 billion in cash, adding Apellis’ rare‑disease drugs Empaveli and Syfovre to its portfolio. The deal expands Biogen’s rare‑disease pipeline as its multiple‑sclerosis revenues decline.